OTLK Outlook Therapeutics

Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital

Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital
EN
07/10/2020

Underlying

OTLKOutlook Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Outlook Therapeutics

 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercia...

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver results ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointmen...

July 1, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break ...

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event Live webcast on Wednesday, June 25th at 12:00 PM ET ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a on Wednesday, June 25, 2025 at 12:00 PM ET. As part of the event, Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer, Jeff Evanson, Chief Commercial Officer and Jedd Comiskey, Senior VP – Head of Europe...

June 18, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevac...

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium (SMC) acceptance of LYTENAVA™ (bevacizumab gamma) for use within NHS Scotland for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only licensed ophthalmic formulation of bevacizum...

June 10, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevaci...

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)2.8 million injections of repackaged off-label bevacizumab in Europe each year1 ISELIN, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (b...

June 2, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offeri...

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of an underwritten public offering of 9,285,714 shares of its common stock, together with accompanying warrants to purchase 18,571,428 shares of its common stock. The combined public offering price of common stock and accompanying warrant is $1.40. The common stock is being sold ...

May 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch